Acadia Pharma (ACAD) Tops Q3 EPS by 17c

Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.09), $0.17 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $131.6 million versus the consensus estimate of $127.75 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c